Ionic Liquid-Mediated siRNA for Transdermal IL-23 Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current siRNA treatments for psoriasis and other IL-23-associated diseases face challenges due to low cell permeability and susceptibility to nuclease degradation, limiting their effectiveness and applicability beyond injectable preparations.
Innovation Solution
Development of a double-stranded RNA (siRNA) targeting the p19 subunit of IL-23, chemically modified for stability, combined with an aliphatic carboxylic acid-based ionic liquid to enhance skin permeability and stability, allowing for transdermal administration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If siRNA is used for transdermal administration, then ease of operation is improved, but reliability deteriorates due to low cell permeability and nuclease degradation
Solution Approach 1:
The patent uses an ionic liquid as an intermediary carrier to deliver siRNA through the skin. The ionic liquid acts as a mediator that facilitates transdermal penetration while protecting siRNA from degradation, enabling both ease of topical administration and reliable drug delivery to target cells.
Solution Approach 2:
The patent creates a composite formulation combining siRNA with ionic liquid. This composite material integrates the therapeutic function of siRNA with the permeation-enhancing and protective properties of ionic liquid, achieving both ease of administration and reliability in terms of stability and cell permeability.
2Reliability
If antibody drugs are used to inhibit IL-23, then therapeutic effect is improved, but device complexity and cost worsen due to injection requirements
Solution Approach 1:
The patent replaces the mechanical injection system with a topical application system. Instead of requiring syringes, needles, and injection procedures, the siRNA is delivered through the skin using a simple topical formulation, eliminating the need for complex injection equipment while maintaining therapeutic effectiveness.
Solution Approach 2:
The patent uses a simple, inexpensive topical formulation instead of expensive antibody drugs requiring injection equipment. The siRNA-based topical preparation is a cost-effective alternative that eliminates the need for costly injection devices and procedures while providing comparable therapeutic benefits.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The modified siRNA effectively inhibits IL-23 expression, improving psoriasis symptoms and demonstrating high stability and skin permeability, enabling a more effective and economical treatment option.
Implementation Method 1
by the use of an ionic liquid, high skin permeability of the double stranded RNA
Implementation Method 2
dissolving the double stranded RNA into the resulting ionic liquid to produce an ionic liquid solution comprising the double stranded RNA
Data Source
AI summary
The present invention provides a novel siRNA specifically inhibiting the expression of IL-23 and a pharmaceutical composition comprising the siRNA specifically a double stranded RNA comprising a sense strand and an antisense strand wherein each strand has 19 to 30 nucleotides and comprises the base sequence selected from SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5 or SEQ ID NO: 6 or a complementary base sequence thereof and a pharmaceutical composition comprising the double stranded RNA.